Current status of photodynamic technology for urothelial cancer
Keiji Inoue1,2, Hideo Fukuhara1,2, Shinkuro Yamamoto1,2
1Department of Urology, Kochi Medical School, Nankoku, Japan.
Abstract:
5-Aminolevulinic acid is a new-generation photosensitizer with high tumor specificity. It has been used successfully in the diagnosis, treatment, and screening of urological cancers including bladder cancer; specifically, it has been used in photodynamic diagnosis to detect tumors by illuminating the lesion with a specific wavelength of light to produce fluorescence in the lesion after administration of 5-aminolevulinic acid, in photodynamic therapy, which induces tumor cell death via production of cytotoxic reactive oxygen species, and in photodynamic screening, in which porphyrin excretion in the blood and urine is used as a tumor biomarker after administration of 5-aminolevulinic acid. In addition to these applications in urological cancers, 5-aminolevulinic acid-based photodynamic technology is expected to be used as a novel strategy for a large number of cancer types because it is based on a property of cancer cells known as the Warburg effect, which is a basic biological property that is common across all cancers.
Insights
5-Aminolevulinic acid (ALA) is a photosensitizer effective for diagnosing and treating urological cancers. Its tumor-specific fluorescence and ability to induce cell death show promise for broader cancer therapy applications.
Area of Science:
- Oncology
- Photodynamic Therapy
- Biochemistry
Background:
- 5-Aminolevulinic acid (ALA) is a novel photosensitizer with demonstrated high tumor specificity.
- ALA has been successfully applied in the diagnosis, treatment, and screening of urological cancers, particularly bladder cancer.
Purpose of the Study:
- To review the applications of ALA in urological cancer management.
- To explore the potential of ALA-based photodynamic technology for a wider range of cancer types.
Main Methods:
- Photodynamic Diagnosis (PDD): Utilizes ALA-induced fluorescence for tumor detection.
- Photodynamic Therapy (PDT): Employs ALA to generate reactive oxygen species for tumor cell death.
- Photodynamic Screening: Monitors porphyrin excretion as a tumor biomarker.
Main Results:
- ALA-PDD effectively detects tumors by specific light excitation, causing fluorescence.
- ALA-PDT induces selective tumor cell death through cytotoxic reactive oxygen species.
- ALA-based photodynamic screening uses porphyrin levels in blood and urine as biomarkers.
Conclusions:
- ALA is a versatile tool for urological cancer diagnosis, treatment, and screening.
- The Warburg effect common to all cancers suggests ALA-based photodynamic technology has broad applicability beyond urological cancers.
